Financiado en parte por Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, H. Lundbeck A/S
A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder
Lyoo IK, Yoon S, Kim TS, Hwang J, Kim JE, Won W, Bae S, Renshaw PF
The American journal of psychiatry · 98 citas
Etiquetas de revisión
Financiado por la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiado por la industria
- Empresa
- Eli Lilly and Company
- Empresa
- AstraZeneca
- Empresa
- GlaxoSmithKline
- Universidad u hospital
- McLean Hospital
- Organización sin fines de lucro
- National Alliance for Research on Schizophrenia and Depression
- Empresa
- H. Lundbeck A/S
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of Mental Health
- Gobierno
- National Institute on Drug Abuse
- Gobierno
- NIH Clinical Center
- Gobierno
- NIDA NIH HHS
- Gobierno
- NIMH NIH HHS
- Gobierno
- Intramural VA
- Subvenciones
- National Institute on Drug Abuse (DA-031247); National Institute on Drug Abuse (R01DA024070); National Institute on Drug Abuse (K05DA031247); National Institute of Mental Health (R33MH096858); National Institute of Mental Health (R01MH058681); National Institute on Drug Abuse (DA015116); National Institute on Drug Abuse (DA024070); National Institute on Drug Abuse (K24 DA015116); National Institute of Mental Health (MH058681); National Institutes of Health (VA999999)
Según 13 financiadores declarados.
Publicación
- Publicado
- 2012-09-01 · Am J Psychiatry · vol. 169 · número 9 · págs. 937–945
- Editorial
- American Psychiatric Association
- Citado
- 133 citas · más que el 98% de estudios similares · 7.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Treatment of Major Depression · Tryptophan and brain disorders · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Palabras clave
- creatine monohydrate, antidepressant augmentation, selective serotonin reuptake inhibitors, escitalopram, major depressive disorder, women, brain bioenergetics, treatment response
- MeSH
- humans, creatine, citalopram, antidepressive agents, drug therapy, combination, administration, oral, double-blind method, adult, aged, middle aged, women's health, female, selective serotonin reuptake inhibitors, major depressive disorder
8 autores
- In Kyoon Lyoo🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Sujung J. Yoon🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Tae Suk Kim🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Jaeuk Hwang🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Jieun E. Kim🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Wang‐Youn Won🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Sujin Bae🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
- Perry Franklin Renshaw🇰🇷🇺🇸Ewha Womans University; Seoul National University; University of Utah; Soonchunhyang University; Catholic University of Korea
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Antidepressants targeting monoaminergic neurotransmitter systems, despite their immediate effects at the synaptic level, usually require several weeks of administration to achieve clinical efficacy. The authors propose a strategy of adding creatine monohydrate (creatine) to a selective serotonin reuptake inhibitor (SSRI) in the treatment of patients with major depressive disorder. Such augmentation may lead to a more rapid onset of antidepressant effects and a greater treatment response, potentially by restoring brain bioenergetics at the cellular level.
Method
Fifty-two women with major depressive disorder were enrolled in an 8-week double-blind placebo-controlled clinical trial and randomly assigned to receive escitalopram in addition to either creatine (5 g/day, N=25) or placebo (N=27). Efficacy was primarily assessed by changes in the Hamilton Depression Rating Scale (HAM-D) score.
Results
In comparison to the placebo augmentation group, patients receiving creatine augmentation showed significantly greater improvements in HAM-D score, as early as week 2 of treatment. This differential improvement favoring creatine was maintained at weeks 4 and 8. There were no differences between treatment groups in the proportion of patients who discontinued treatment prematurely (creatine: N=8, 32.0%; placebo: N=5, 18.5%) or in the overall frequency of all reported adverse events (creatine: 36 events; placebo: 45 events).
Conclusions
The current study suggests that creatine augmentation of SSRI treatment may be a promising therapeutic approach that exhibits more rapid and efficacious responses in women with major depressive disorder.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.